Eledon Pharmaceuticals: 2025 Milestones and 2026 Outlook
IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) announced significant achievements from 2025 and outlined its business expectations for 2026. The company reported favorable results from its Phase 2 BESTOW clinical trial for tegoprubart, an innovative therapy for kidney transplantation, along with promising data from ongoing studies in type 1 diabetes and xenotransplantation.
Key Milestones Achieved in 2025
- Successful Phase 2 BESTOW Trial: Eledon presented data showing excellent safety and tolerability of tegoprubart, significantly reducing the toxicities associated with the standard immunosuppressant, tacrolimus.
- Kidney Function Improvements: Participants on tegoprubart had a mean estimated glomerular filtration rate (eGFR) of 69 mL/min/1.73 m² at 12 months, potentially the highest reported in recent kidney transplant trials.
- Non-Inferiority to Tacrolimus: The rejection rates for patients on tegoprubart were 22.2%, compared to 17.2% for those on tacrolimus, demonstrating the drug's non-inferiority in preventing organ rejection.
- Positive Outcomes in Type 1 Diabetes: In a separate study at UChicago Medicine, six patients achieved complete insulin independence after receiving tegoprubart as part of their islet transplantation regime.
- Xenotransplantation Advancements: Tegoprubart was utilized as a key immunosuppressant in a genetically modified pig kidney transplant at Massachusetts General Hospital.
- Strong Financial Backing: Eledon successfully completed a $57.5 million public offering to support its operations through 2027.
2026 Anticipated Developments
Looking ahead, Eledon plans to present critical data and begin new studies that will further explore the potential of tegoprubart. Key milestones for 2026 include:
- Sharing 24-month data from ongoing research on tegoprubart at the American Society of Transplant Surgeons Winter Symposium.
- Engaging with the FDA on Phase 3 trial designs for tegoprubart in kidney transplantation.
- Updating results from the Phase 1 and Phase 2 BESTOW studies and investigating expanded applications in islet cell transplantation and kidney transplant tolerance.
CEO's Perspective on Progress
According to Dr. David-Alexandre Gros, CEO of Eledon, “2025 was a significant year for Eledon as we achieved multiple key milestones across our clinical programs. The results from the Phase 2 BESTOW trial validate our approach, showcasing the potential of tegoprubart as a safer alternative to tacrolimus-based immunosuppression.”
About Eledon Pharmaceuticals and Tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company committed to developing immune-modulating therapies for life-threatening conditions. Tegoprubart, an anti-CD40L antibody, offers a non-lymphocyte depleting immunotherapy that targets the CD40 Ligand, exhibiting broad therapeutic applications in organ transplantation and other conditions.
Headquartered in Irvine, California, Eledon aims to enhance treatment outcomes through innovative therapies. For more information, visit www.eledon.com.
Forward-Looking Statements
This announcement contains forward-looking statements, including anticipated timelines for clinical trials and the expected impact of upcoming studies. Actual results may differ, and Eledon encourages interested parties to consider the associated risks and uncertainties.